Alan is CEO of IP Group Plc. Previously he was founder and CEO of Techtran Group Ltd, which was acquired by IP Group Plc in January 2005, and was formerly a partner in KPMG where he specialised in corporate finance advice to technology-based fast growth businesses. He has worked on over 75 transactions helping businesses to raise more than £200m. Alan is a qualified Chartered Accountant and holds a BA in Economics from University of Leeds and an MBA from the University of Bradford. He is also a member and fellow of the corporate finance and IT faculty of the Institute of Chartered Accountants.

Sam has over ten years’ experience in the financial services industry focusing on biotechnology, most recently at Lehman Brothers where he held the position of Industry Group Leader for European Pharmaceuticals and Chemicals. Sam was ranked the number one European Biotechnology equity analyst by Institutional Investor magazine in 2004, 2005 and 2006 and by Thomson Extel in 2004 and 2005. Sam has a PhD from the Laboratory of Molecular Biology in Cambridge where he worked in the research group of Sir Gregory Winter FRS, scientific co-founder of Cambridge Antibody Technology (CAT) and Domantis.

Ian was one of the founders of Pharmaceutical Profiles, a successful spin-out company from Nottingham University. Prior to an MBO in January 2005, Ian had served as the Chief Executive and Chairman of the company, specializing in early phase clinical trials for over 15 years. He has published over 250 research papers/abstracts in the area of drug absorption /delivery and in 2005 received the CRS "Career Achievement Award in Oral Drug Delivery". In 1997 he served as an expert scientist for the FDA and is recognized globally as an innovator in early drug development.